Roche Molecular Systems, Inc. v. Cepheid, No. 17-1690 (Fed. Cir. Oct. 9, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellant Roche Molecular Systems, Inc. (“Roche”) owns U.S. Patent No. 5,643,723 (“the ’723 patent”) , titled “Detection of a Genetic Locus Encoding Resistance to Rifampin in Microbacterial Cultures and in Clinical Specimens.” The United States District Court for the Northern District of California found that the asserted claims of the ’ 723 patent are di rected to patent -ineligible subject matter and are therefore invalid under 35 U.S.C. § 101. Roche appeals from a grant of summary judgment of invalidity. We affirm. I.